Article

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer

Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
Journal of Translational Medicine (Impact Factor: 3.99). 08/2010; 8:78. DOI: 10.1186/1479-5876-8-78
Source: PubMed

ABSTRACT We recently demonstrated that increased expression of the RNA-binding protein RBM3 is associated with a favourable prognosis in breast cancer. The aim of this study was to examine the prognostic value of RBM3 mRNA and protein expression in epithelial ovarian cancer (EOC) and the cisplatin response upon RBM3 depletion in a cisplatin-sensitive ovarian cancer cell line.
RBM3 mRNA expression was analysed in tumors from a cohort of 267 EOC cases (Cohort I) and RBM3 protein expression was analysed using immunohistochemistry (IHC) in an independent cohort of 154 prospectively collected EOC cases (Cohort II). Kaplan Meier analysis and Cox proportional hazards modelling were applied to assess the relationship between RBM3 and recurrence free survival (RFS) and overall survival (OS). Immunoblotting and IHC were used to examine the expression of RBM3 in a cisplatin-resistant ovarian cancer cell line A2780-Cp70 and its cisplatin-responsive parental cell line A2780. The impact of RBM3 on cisplatin response in EOC was assessed using siRNA-mediated silencing of RBM3 in A2780 cells followed by cell viability assay and cell cycle analysis.
Increased RBM3 mRNA expression was associated with a prolonged RFS (HR = 0.64, 95% CI = 0.47-0.86, p = 0.003) and OS (HR = 0.64, 95% CI = 0.44-0.95, p = 0.024) in Cohort I. Multivariate analysis confirmed that RBM3 mRNA expression was an independent predictor of a prolonged RFS, (HR = 0.61, 95% CI = 0.44-0.84, p = 0.003) and OS (HR = 0.62, 95% CI = 0.41-0.95; p = 0.028) in Cohort I. In Cohort II, RBM3 protein expression was associated with a prolonged OS (HR = 0.53, 95% CI = 0.35-0.79, p = 0.002) confirmed by multivariate analysis (HR = 0.61, 95% CI = 0.40-0.92, p = 0.017). RBM3 mRNA and protein expression levels were significantly higher in the cisplatin sensitive A2780 cell line compared to the cisplatin resistant A2780-Cp70 derivative. siRNA-mediated silencing of RBM3 expression in the A2780 cells resulted in a decreased sensitivity to cisplatin as demonstrated by increased cell viability and reduced proportion of cells arrested in the G2/M-phase.
These data demonstrate that RBM3 expression is associated with cisplatin sensitivity in vitro and with a good prognosis in EOC. Taken together these findings suggest that RBM3 may be a useful prognostic and treatment predictive marker in EOC.

Download full-text

Full-text

Available from: Fredrik Pontén, Jul 14, 2015
0 Followers
 · 
150 Views
  • Source
    • "The negative correlation between RBM3 and Chk1/Chk2 further emphasizes that RBM3 expression may predict response to platinum-based chemotherapy by silencing these important regulators of cellular DNA damage response. Inhibition of Chk1 and ATR was recently shown to generate the greatest impact on cisplatin response in ovarian cancer cell lines as illustrated in an RNAi screen [36], which might, in part, explain the cisplatin-sensitizing effect of RBM3 that we have previously described [11]. Inhibition of Chk1 has been reported to sensitize tumor cells to chemotherapy in various cell lines [37] [38] [39], and several Chk1 inhibitors have been developed and evaluated in clinical trials [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The RNA-binding motif protein 3 (RBM3) was initially discovered as a putative cancer biomarker based on its differential expression in various cancer forms in the Human Protein Atlas (HPA). We previously reported an association between high expression of RBM3 and prolonged survival in breast and epithelial ovarian cancer (EOC). Because the function of RBM3 has not been fully elucidated, the aim of this study was to use gene set enrichment analysis to identify the underlying biologic processes associated with RBM3 expression in a previously analyzed EOC cohort (cohort 1, n = 267). This revealed an association between RBM3 expression and several cellular processes involved in the maintenance of DNA integrity. RBM3-regulated genes were subsequently screened in the HPA to select for putative prognostic markers, and candidate proteins were analyzed in the ovarian cancer cell line A2780, whereby an up-regulation of Chk1, Chk2, and MCM3 was demonstrated in siRBM3-treated cells compared to controls. The prognostic value of these markers was assessed at the messenger RNA level in cohort 1 and the protein level in an independent EOC cohort (cohort 2, n = 154). High expression levels of Chk1, Chk2, and MCM3 were associated with a significantly shorter survival in both cohorts, and phosphorylated Chk2 was an adverse prognostic marker in cohort 2. These results uncover a putative role for RBM3 in DNA damage response, which might, in part, explain its cisplatin-sensitizing properties and good prognostic value in EOC. Furthermore, it is demonstrated that Chk1, Chk2, and MCM3 are poor prognostic markers in EOC.
    Translational oncology 08/2011; 4(4):212-21. DOI:10.1593/tlo.11106 · 3.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents a 30 GHz-band oscillator with a temperature stable dielectric resonator (DR). The DR is formed incorporating metalized through holes in a dielectric substrate. An oscillator MMIC is stacked on the DR using flip-chip bonding. A fabricated dielectric resonator oscillator (DRO) shows an output power of larger than +10 dBm and a phase noise of less than -90 dBc/Hz at 1 MHz-offset with an oscillation frequency of around 31.7 GHz. The frequency change is ±315 ppm over a temperature range from -25 to +100 °C. The size of the DRO is 4.3 mm × 3.8 mm × 0.4 mm.
    Microwave Symposium Digest, 2004 IEEE MTT-S International; 07/2004
  • Source
    Journal of Obstetrics and Gynecology of India 02/2011; 61(1):27-31. DOI:10.1007/s13224-011-0013-z
Show more